CANNABIS EXPLAINER
From the 2-minute onset of a dab to the 8-hour arc of a high-dose edible, the method you choose changes everything. Complete comparison of all 9+ methods with onset, duration, bioavailability, and harm-reduction guidance.
| Method | Onset | Duration | Bioavailability | Discreet | Lung Risk | Dose Control |
|---|---|---|---|---|---|---|
| Smoking (joint/pipe/bong) | 2–10 min | 1–3 h | 20–35% | Low | High (combustion) | Low |
| Dry Herb Vaporizer | 5–15 min | 1–3 h | 40–55% | Medium | Low (no combustion) | Medium |
| Concentrate Dabs | 1–3 min | 1–3 h | 40–60% | Low | Medium (very hot vapor) | Low (very potent) |
| Vape Pen (cartridge) | 3–8 min | 1–2.5 h | 40–55% | High | Low–Medium | Medium |
| Edibles | 30–120 min | 4–8 h | 6–20% | High | None | Low (delayed onset) |
| Tincture (sublingual) | 15–45 min | 2–4 h | 20–35% | High | None | High |
| Capsules / Pills | 45–120 min | 4–8 h | 6–20% | Very High | None | High |
| Topicals | 15–30 min (local) | 2–4 h (local) | ~0% systemic | Very High | None | N/A |
| Transdermal Patches | 30–90 min | 6–12 h | 35–60% | Very High | None | Medium |
| Beverages (standard) | 30–90 min | 3–6 h | 6–15% | High | None | Medium |
| Beverages (nano-emulsion) | 15–30 min | 2–4 h | 20–30% | High | None | Medium–High |
Smoking remains the most widely practiced consumption method globally. Combustion of cannabis flower at approximately 700–900°C produces a complex aerosol containing cannabinoids, terpenes, and — unavoidably — combustion byproducts including carbon monoxide, polycyclic aromatic hydrocarbons (PAHs), and fine particulate matter. The psychoactive onset of 2–10 minutes, driven by direct alveolar absorption, makes titration practical for experienced consumers.
Joints (rolled in paper) allow full-flavor terpene expression but produce continuous sidestream smoke. Pipes concentrate the smoke into smaller, more potent hits. Bongs use water filtration that cools the smoke and removes some particulates, though research indicates water filtration removes relatively little of the harmful gas-phase compounds. Blunts (cigar wraps) add tobacco-derived nicotine and compounds, compounding the respiratory risk. Water pipes do reduce some irritant compounds but should not be considered a “safe” smoking method.
Dry herb vaporizers heat cannabis flower to temperatures between 160 and 230°C — hot enough to volatilize cannabinoids and terpenes, but below the 230°C combustion threshold. Studies from Leiden University and subsequent analyses have demonstrated that vaporization produces vapor with over 95% fewer carcinogenic compounds than combustion at comparable cannabinoid delivery. The 2007 Abrams study found no adverse pulmonary function changes in vaporizer users over 6 months.
Temperature selection is pharmacologically meaningful: 170–185°C primarily vaporizes terpenes and THC; 185–200°C adds CBD, CBG, and higher-boiling terpenes; 200–220°C delivers CBN and maximum potency but increases pyrolysis byproducts. Most experienced users target the 185–195°C window as the optimal balance.
Cannabis concentrates — wax, shatter, live resin, rosin, distillate — are consumed via dab rigs (heated nail or electronic nail), vape cartridges, or portable pens. THC content ranges from 60% in basic wax to 90%+ in distillate. The pharmacokinetics are similar to vaporization, with onset under 3 minutes and a very steep dose-response curve.
Dabbing at temperatures above 250°C degrades terpenes and produces degradation products including methacrolein and benzene. “Low-temp dabs” at 160–200°C preserve the terpene profile and reduce these risks. Concentrates represent the highest-bioavailability inhalation method but also carry the highest risk of overconsumption, tolerance escalation, and cannabinoid hyperemesis syndrome (CHS) in heavy chronic users.
Oral cannabis — brownies, gummies, chocolates, capsules, cooking infusions — undergoes first-pass hepatic metabolism. THC is converted by the liver enzyme CYP2C9 into 11-hydroxy-THC (11-OH-THC), a metabolite that crosses the blood-brain barrier 4–5 times more efficiently than THC itself. This metabolic conversion is responsible for the distinct character of edible effects — often described as more intense, more full-body, and less controllable than inhalation at equivalent THC doses.
Bioavailability of oral cannabis is highly variable (6–20%) and depends on fed/fasted state (fatty meals significantly increase absorption), individual CYP2C9 enzyme activity (poor metabolizers absorb more; ultrarapid metabolizers absorb less), and the specific formulation of the product.
| Method | Bioavailability | Absorption Route | Key Variable | Clinical Source |
|---|---|---|---|---|
| Smoking | 20–35% | Pulmonary alveoli → blood | Inhalation depth, breath-hold duration | Grotenhermen 2003; Huestis 2007 |
| Dry Herb Vaporizing | 40–55% | Pulmonary alveoli → blood | Temperature setting, draw speed | Abrams 2007; Hazekamp 2016 |
| Concentrates (dabbing) | 40–60% | Pulmonary alveoli → blood | Nail temperature, concentrate type | Raber 2015; extrapolated from vaping data |
| Sublingual tincture | 20–35% | Oral mucosa → portal circulation | Hold time under tongue (60–90 sec) | Karschner 2011; Niesink 2015 |
| Oral (edibles/capsules) | 6–20% | GI tract → hepatic first-pass | Fed state, CYP2C9 polymorphism, food fat content | Ohlsson 1980; Mechoulam 2002 |
| Transdermal patch | 35–60% | Skin permeation → systemic circulation | Skin integrity, application site, occlusion | Stinchcomb 2004; Cannabis patch studies 2016 |
| Topical (standard) | ~0% systemic | Local dermis CB2 receptors only | Formulation depth penetration | Hammell 2016 (transdermal model reference) |
Tinctures (sublingual) offer the best balance of onset speed and precision dosing for medical users. Held under the tongue for 60–90 seconds, cannabinoids absorb through the oral mucosa directly into the bloodstream, bypassing first-pass metabolism partially. Standard onset is 15–45 minutes with a 2–4 hour duration. Available in alcohol-based (higher bioavailability) and MCT oil-based formulations.
Capsules and pills behave pharmacokinetically identically to edibles — they undergo the same hepatic first-pass metabolism with the same 6–20% bioavailability and 45–120 minute onset. Their advantage is dose precision and consistency across batches.
Topicals (creams, salves, balms) interact with cannabinoid receptors in skin, underlying muscle, and local nerve tissue. CBD topicals have demonstrated efficacy for localized inflammation, neuropathic pain, and skin conditions. They do not produce psychoactive effects. Transdermal patches are specifically formulated with penetration enhancers to drive cannabinoids through the skin into systemic circulation. They can produce psychoactive effects and have higher bioavailability than oral methods.
Beverages fall into two categories: standard cannabis beverages behave like edibles with the same slow onset. Nano-emulsion beverages use ultrasonic or high-pressure homogenization to reduce THC droplet size to 20–200nm, enabling lymphatic absorption that bypasses hepatic first-pass metabolism and reduces onset to 15–30 minutes — making them the most predictable oral consumption format currently available.
| Goal / Need | Best Method | Reason | Avoid |
|---|---|---|---|
| Insomnia / sleep | Edibles or capsules (5–10mg) | Long duration (4–8h) covers sleep cycle; consistent onset once calibrated | Dabs — too potent, disrupts REM |
| Acute pain relief | Vaporizer or tincture | Fast onset enables titration; tincture avoids lung exposure | Topical for deep/systemic pain |
| Anxiety management | Tincture (CBD-dominant) or low-dose vaporizer | Sublingual allows precise dosing; vaporizer allows real-time titration | High-THC edibles — unpredictable, anxiety risk |
| Recreational / social | Joint, vape pen, or nano beverage | Fast onset, known duration, social format | Edibles unless experienced — onset delayed |
| Maximum discretion | Capsule, transdermal patch, or tincture | Odorless, no paraphernalia, controlled release | Smoking / dabbing |
| Localized muscle / joint pain | Topical cream or salve | Targets CB2 receptors at site; no systemic effects | Oral if only local relief needed |
| Medical (chronic condition) | Capsule or tincture with physician guidance | Consistent dosing, COA verification, controlled delivery | Unregulated products |
| New consumer | Low-dose vaporizer (1–2 draws) or micro-dose edible (2.5mg) | Controllable onset; low dose ceiling | Concentrates or high-THC edibles |
| Method | Primary Risk | Mitigation Strategy |
|---|---|---|
| Smoking | Combustion byproducts — respiratory irritation, chronic bronchitis risk with heavy use | Switch to dry herb vaporizer; avoid tobacco mixing; use filtered water pipe |
| Vaporizing | Device contamination (some cartridges contain cutting agents); battery/coil safety | Use regulated devices; check COA for diluents; avoid unbranded cartridges |
| Concentrates / Dabs | Overconsumption due to potency; CHS risk in chronic heavy users; high-temp degradation products | Low-temp dabs only (<220°C); track consumption; tolerance breaks regularly |
| Edibles | Overconsumption from delayed onset — leading cause of cannabis-related ER visits | Wait minimum 2 hours before redosing; start at 2.5–5mg; avoid alcohol co-use |
| Tinctures | Inaccurate dosing with dropper; alcohol-based products can irritate sensitive users | Use calibrated syringes; MCT tincture for sensitive users; verify COA potency |
| Topicals | Contaminated products with untested ingredients; false medical claims | Purchase from licensed producers; check COA for cannabinoid content |
| Transdermal | Skin irritation; can produce systemic psychoactive effects unexpectedly | Patch on clean, intact skin; know the THC dose; remove if adverse effects occur |